Claim: A new lung cancer drug has been authorised under an international scheme that the UK has been able to join post Brexit.
Fact-check: Conflicting claims about 'new' cancer drug thanks to Brexit are both misleading - Full Fact
Verdict: the medication has had eu authorisation since 2016 but the recent authorisation has allowed a new use of the medication, earlier in the disease. this has not yet been authorised in the eu.
Organisation: Full Fact
Author: Daniella De Block Golding
Date published: 2021-05-11T00:00:00